Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

143.14 +0.88 (+0.62%)
Streaming Delayed Price Updated: 2:17 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 390,042
Open 142.10
Bid (Size) 142.93 (2)
Ask (Size) 143.20 (2)
Prev. Close 142.26
Today's Range 141.67 - 144.32
52wk Range 110.03 - 192.16
Shares Outstanding 145,800,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity
William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therapy pipeline. 
Via Benzinga
3 Reasons BIIB is Risky and 1 Stock to Buy Instead
Biogen has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 26.6% to $146 per share while the index has gained 26.5%. 
Via StockStory
Topics Government Stocks World Trade

Performance

YTD
-4.6%
-4.6%
1 Month
-0.4%
-0.4%
3 Month
+11.2%
+11.2%
6 Month
+20.7%
+20.7%
1 Year
-24.3%
-24.3%

More News

Read More
1 Healthcare Stock to Research Further and 2 We Find Risky
Via StockStory
Topics Stocks
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”
From Biogen Inc.
Via GlobeNewswire
Reflecting On Therapeutics Stocks’ Q2 Earnings: Amgen (NASDAQ:AMGN)
Via StockStory
Topics Artificial Intelligence
UnitedHealth, Brookdale, Collegium Pharmaceutical, QuidelOrtho, and Biogen Shares Are Falling, What You Need To Know
Via StockStory
Topics Economy Government World Trade
7 Analysts Have This To Say About Biogen
Via Benzinga
Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
From Stoke Therapeutics, Inc.
Via Business Wire
Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
From Biogen Inc.
Via GlobeNewswire
1 Value Stock with Promising Prospects and 2 We Avoid
Via StockStory
Ionis Pharmaceuticals (NASDAQ:IONS) Ascends to Six-Year High, Fueled by Breakthrough Pipeline and Robust Sales Outlook
Via MarketMinute
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
Which S&P500 stocks are moving on Monday?
Via Chartmill
Nasdaq 100 Top 25,000 As AMD Spikes, Gold Eyes $4,000: What's Moving Markets Monday?
Via Benzinga
Monday's session: top gainers and losers in the S&P500 index
Via Chartmill
Breakthrough in Alzheimer’s Diagnostics: University of Liverpool Unveils Low-Cost, Handheld AI Blood Test
Via TokenRing AI
Topics Artificial Intelligence
Which S&P500 stocks are gapping on Monday?
Via Chartmill
Decoding Life's Blueprint: New Tech Maps RNA-Protein Interactions, Unlocking Disease Cures
Via MarketMinute
Topics Artificial Intelligence Derivatives
3 Low-Volatility Stocks That Concern Us
Via StockStory
A Look Back at Therapeutics Stocks’ Q2 Earnings: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Pack
Via StockStory
Topics Artificial Intelligence
Biogen Soars 9.02% on Groundbreaking Alzheimer's Drug Advancements: A New Era for Dementia Treatment Dawns
Via MarketMinute
Trump-Pfizer Deal Pushes Health Care Stocks To Best Rally In 5 Years
Via Benzinga
Topics Government
Wednesday's session: top gainers and losers in the S&P500 index
Via Chartmill
Health Care Stocks Rally, Nike Beats The Street: What's Moving Markets Wednesday?
Via Benzinga
Which S&P500 stocks are moving on Wednesday?
Via Chartmill

Frequently Asked Questions

Is Biogen Idec publicly traded?
Yes, Biogen Idec is publicly traded.
What exchange does Biogen Idec trade on?
Biogen Idec trades on the Nasdaq Stock Market
What is the ticker symbol for Biogen Idec?
The ticker symbol for Biogen Idec is BIIB on the Nasdaq Stock Market
What is the current price of Biogen Idec?
The current price of Biogen Idec is 143.14
When was Biogen Idec last traded?
The last trade of Biogen Idec was at 10/17/25 02:17 PM ET
What is the market capitalization of Biogen Idec?
The market capitalization of Biogen Idec is 20.87B
How many shares of Biogen Idec are outstanding?
Biogen Idec has 21B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.